Vaccine formulations comprising saponin-containing adjuvants

Patent metadata

Field	Value
Publication number	US-9730987-B2
Application number	US-201514632863-A
Country	US
Kind code	B2
Filing date	Feb 26, 2015
Priority date	Sep 10, 2009
Publication date	Aug 15, 2017
Grant date	Aug 15, 2017

Abstract

The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

First claim

What is claimed is:

1. A safe and effective stable injectable oil-in-water (O/W) vaccine emulsion, wherein the emulsion is effective for eliciting a protective immunologic response in a porcine vaccinate, comprising:
(i) at least about 10 μg of antigen/2 mL vaccine dose, wherein the antigen is foot and mouth disease virus (FMDV), dissolved in the aqueous phase of the emulsion;
(ii) 0.7 to about 1.3 mg/2 mL vaccine dose of a saponin, dissolved in the aqueous phase of the emulsion; wherein the saponin consists of an anion-exchange column purified extract of Quillaja saponaria Molina bark enriched for QS-17, QS-18 and QS-21;
(iii) about 0.37% to about 0.42% w/v (of the emulsion) aluminum hydroxide, dissolved in the aqueous phase of the emulsion;
(iv) a mineral oil, present in an amount of about 20% to about 40% of the emulsion;
(v) a non-ionic lipophilic surfactant, present in the amount of 0.1% to about 2.5% w/v of the emulsion, and selected from sorbitan fatty acid monoesters, fatty acid esters of mannide, ethoxylated fatty acid esters of mannide, and combinations thereof;
(vi) a non-ionic hydrophilic surfactant, present in the amount of 0.1% to about 1.5% w/v of the emulsion, and having a high hydrophilic-lipophilic balance (HLB) value between 13 and 40 selected from ethoxylated fatty acid monoesters of sorbitan, ethoxylated fatty acids, and combinations thereof; and
(vii) a non-ionic hydrophilic surfactant present, in the amount of about 1% to about 8% w/v of the emulsion, and having a low hydrophilic-lipophilic balance (HLB) value between 9 and 13 selected from ethoxylated fatty acid triesters of sorbitan, ethoxylated fatty acid diesters of sorbitan, ethoxylated fatty acid monoesters of sorbitan, ethoxylated fatty acids, ethoxylated castor oil and, combinations thereof;
wherein the final HLB of the emulsion is from about 9 to about 12; and
wherein the emulsion remains a stable O/W emulsion for at least 24 months; and
wherein the only oil present in the emulsion is the mineral oil.

2. The emulsion of claim 1 , wherein the concentration of the aluminum hydroxide is about 0.42% (w/v).

3. The emulsion of claim 1 , wherein the amount of antigen is at least about 60 μg per 2 mL vaccine dose.

4. The emulsion of claim 1 , wherein the amount of saponin is 0.7 mg/dose.

5. The emulsion of claim 1 , wherein the amount of saponin is about 1.3 mg/2 mL vaccine dose.

6. The emulsion of claim 1 , wherein the antigen further comprises a bacterial antigen.

7. The emulsion of claim 1 , wherein the antigen consists essentially of a combination of an FMDV antigen, a PCV2 antigen and a bacterial antigen.

8. The emulsion of claim 1 , wherein the high HLB non-ionic hydrophilic surfactant is present at a concentration of 0.4% to 1.2% expressed as a weight by volume of emulsion (w/v), and wherein the percentage of the surfactants is from about 4% to about 8% weight/volume.

9. The emulsion of claim 1 , wherein the low HLB non-ionic hydrophilic surfactant is present at a concentration of 2.5% to 4% expressed as a weight by volume of emulsion (w/v).

10. The emulsion of claim 1 , wherein the non-ionic lipophilic surfactant is present at a concentration of 0.2% to 1.2% expressed as a weight by volume of emulsion (w/v).

11. The emulsion of claim 1 , wherein the low HLB non-ionic hydrophilic surfactant is an ethoxylated fatty acid triester of sorbitan, and wherein the ester of said ethoxylated fatty acid ester is selected from the group consisting of oleate, palmitate, stearate, isostearate, laurate and combinations thereof.

12. The emulsion of claim 1 , wherein the non-ionic lipophilic surfactant is a fatty acid ester of sorbitan, and wherein the ester of the fatty acid ester is selected from the group consisting of oleate, palmitate, stearate, isostearate, laurate and combinations thereof.

13. The emulsion of claim 1 , wherein the high HLB non-ionic hydrophilic surfactant is an ethoxylated fatty acid monoester of sorbitan, and wherein the ethoxylated monoester of sorbitan is selected from the group consisting of ethoxylated sorbitan monolaurate, ethoxylated sorbitan monopalmitate, ethoxylated sorbitan monostearate, ethoxylated sorbitan monooleate, and combinations thereof.

14. A method for inducing an immunological response in an porcine against a pathogen comprising administering to said animal the emulsion of claim 1 .

15. The method of claim 14 , wherein the emulsion is administered via the intramuscular (IM), intradermal (ID) or subcutaneous (SC) route, or wherein the administration is done with a needleless injector.

Assignees

• Merial Inc

Inventors

• Detraz Noel Joseph Francois
• Rigaut Guillaume

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P33/00

  Antiparasitic agents · CPC title

• A61P31/20

  for DNA viruses · CPC title